PARP Inhibitors

PARP Inhibitors

Competitor Analysis

The present Competitive Intelligence Report about PARP Inhibitors provides a competitor evaluation in the field of investigational small molecules inhibiting poly-adenyl-ribose polymerase (PARP) for treatment of cancer as of April 2009.

Poly (ADP-ribose) polymerases (PARPs) are a family of nuclear enzymes implicated in the regulation of multiple physiological cellular functions, including DNA repair, gene transcription, protein modification and cell signaling. Over-activation of PARP results in pathologic alteration of cellular metabolism, activation of inflammatory pathways, perturbation of cellular energetics, and cell death through necrosis or apoptosis. Because of its involvement in DNA repair, PARP has been implicated in the development of anti-tumor drug resistance. Targeting PARP is an approach in solid tumor therapy for potentiating the effects of chemotherapy and of radiation therapy and for potentially reducing antitumor drug resistance or resensitizing resistant patients to antitumor therapies. The most advanced projects are in phase II studies of solid tumors.

The report includes a compilation of current active projects in research and development of PARP targeting small molecules. In addition, the report lists company-specific R&D pipelines of EpCAM Antagonists. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

Contents

Index

- PARP Inhibitors in Oncology
- Corporate PARP Inhibitor R&D Pipelines
- About La Merie

Related products

Proteasome Inhibitors Competitor Analysis Product description The present Competitive Intelligence Report about Proteasome Inhibitors provides a competitor evaluation in the field of novel small molecules and peptides targeting the proteasome for treatment of cancer as...

Sodium-dependent glucose (co-) transporter (SGLT) Inhibitors Competitor Analysis Product description The Competitive Intelligence Report Sodium-Dependent Glucose (Co)Transporter (SGLT) Inhibitors as of November 2008 provides a competitor analysis in the development pipeline of novel SGLT inhibitors for treatment of type...

Breast Cancer Drugs World Market Prospects 2010-2025 How will expanding patient populations, improved diagnosis and new treatments benefit this market? The breast cancer treatments market generated pharmaceutical revenues of over $11bn worldwide in 2009. The incidence and prevalence of...

Kinase Inhibitors: Global Markets This Report: Forecasts for the global market, providing data for the years 2005 through 2008, and projections for the market and compound annual growth rates (CAGRs) through 2014 An overview of the...

Stomach Cancer Pipeline Assessment and Market Forecasts to 2017 Stomach Cancer - Pipeline Assessment and Market Forecasts to 2017 Summary GlobalData's report, Stomach Cancer - Pipeline Assessment and Market Forecasts to 2017, is an essential source of information and analysis on...

c-MET/HGF Inhibitors Competitor Analysis Product description The Competitive Intelligence Report c-MET/HGF Inhibitors as of October 2008 provides a competitor analysis in the development pipeline of novel emerging inhibitors of c-MET receptor tyrosine kinase (RTK) and...

Aurora Kinase Inhibitors Competitor Analysis The present Competitive Intelligence Report about Aurora Kinase Inhibitors provides a competitor evaluation in the field of synthetic molecules targeting aurora kinase for treatment of cancer as of June 2009. Mitosis,...

Protein Kinase C (PKC) Inhibitors Competitor Analysis Product description The present Competitive Intelligence Report about new developments in the pipeline of inhibitors of the protein kinase C (PKC) provides a competitor evaluation in the field of R&D projects...

CHK and KSP/Eg5 Inhibitors Competitor Analysis The present Competitive Intelligence Report about checkpoint kinase (CHK) and kinesin spindle protein (KSP) or Eg5 inhibitors provides a competitor evaluation in the field of novel molecular entities inhibiting CHK...

Dipeptidyl peptidase IV (DPP-IV) Inhibitors Competitor Analysis Product description The Competitive Intelligence Report Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors as of November 2008 provides a competitor analysis in the development pipeline of novel DPP-IV inhibitors for treatment of type 2...

Oncology Pipeline Database: 1-Year Subscription Subscription to La Merie's proprietary Oncology Pipeline Database provides online access to more than 3,000 project entries in oncology. Each project is specified for its Target or Mechanism of Action,...

Flat-Rate Subscription to La Merie Reports with 24/7 Online Access Subscription to this product provides online access during one year to all reports published by La Merie and available in the online store during the subscription. Among La Merie reports...

Competitor Analysis: Phosphodiesterase-4 (PDE-4) Inhibitors Product description The present Competitive Intelligence Report about PDE-4 Inhibitors provides a competitor evaluation in the field of small molecules specifically or unspecifically inhibiting phosphodiesterase 4 (PDE-4) as of January 2010....

Protease Inhibitors Innovation Drives Drug Pipeline Proteases constitute one of the largest potential drug target enzyme families, with 647 human gene products incorporating protease sequences and mutated proteases having been identified. In addition, there are...

Raf Inhibitors Competitor Analysis The present Competitive Intelligence Report about Raf inhibitors provides a competitor evaluation in the field of synthetic molecules targeting Raf and mutant Raf (V600E) for treatment of cancer as of...

p38 MAPK Inhibitors Competitor Analysis Product description The present Competitive Intelligence Report about p38 MAPK inhibitors used to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, COPD or pain, respectively, provides a competitor evaluation in the...

Iniparib Failure: Highlights the Uncertainty in Late Stage Breast Cancer Pipeline Summary GlobalData's report, "Iniparib Failure - Highlights the Uncertainty in Late Stage Breast Cancer Pipeline" provides key information on current available treatment of Alzheimer's disease, drivers and barriers for the future...

Competitor Analysis: Notch Pathway Inhibitors Product description The present Competitive Intelligence Report about Notch Pathway Inhibitors provides a competitor evaluation in the field of molecules targeting Notch via gamma-secretase or its vascular ligand delta-like ligand-4 (DLL4)...

Syk Kinase Inhibitors Brief Report Product description The present Brief Report about small molecules and small interfering RNA (siRNA) targeting spleen tyrosine kinase (syk) provides a competitor analysis of these anti-inflammatory molecules. R&D projects of syk...

Elastase Inhibitors Competitor Analysis The present Competitive Intelligence Report about elastase inhibitors provides a competitor evaluation in the field of human plasma-derived, recombinant, transgenic, synthetic and gene therapeutic approaches for treatment of lung emphysema...

20th European Stroke Conference Post Conference Review and Analysis Summary GlobalData, the industry analysis specialist, has released its new conference alerts, "20th European Stroke Conference - Post Conference Review and Analysis". The conference alert is an essential source of information...

Janus Kinase (JAK) Inhibitors Competitor Analysis Product description The present Competitive Intelligence Report about new developments in the pipeline of inhibitors of the janus-associated kinase (JAK) provides a competitor evaluation in the field of active R&D projects...

MEK Inhibitors Competitor Analysis The present Competitive Intelligence Report about MEK Inhibitors provides a competitor evaluation in the field of synthetic molecules targeting MEK pathway for treatment of cancer as of June 2009. The mitogen...

Plk-1 Inhibitors Competitor Analysis The present Competitive Intelligence Report about Plk-1 Inhibitors provides a competitor evaluation in the field of synthetic molecules targeting the polo-like kinase 1 for treatment of cancer as of May...

Ras-Raf-MEK-ERK Inhibitors Competitor Analysis The present Competitive Intelligence report about Ras-Raf-MEK-ERK Inhibitors provides a competitor evaluation in the field of synthetic and biologic molecules targeting the Ras-Raf-MEK-ERK pathway for treatment of cancer as of...

View all products in this category